We have reported that prothrombin (1 M) is able to replace high molecular weight kininogen (45 nM) as a cofactor for the specific binding of factor XI to the platelet (Baglia, F. A., and Walsh, P. N. (1998) Biochemistry 37, 2271-2281). We have also determined that prothrombin fragment 2 binds to the Apple 1 domain of factor XI at or near the site where high molecular weight kininogen binds. A region of 31 amino acids derived from high molecular weight kininogen (HK31-mer) can also bind to factor XI (Tait, J. 
Coagulation factor XI (FXI)
1 is a disulfide-linked homodimeric protein (160,000 Da) (1) that is cleaved by thrombin, FXIIa, or FXIa at a single peptide bond (Arg 369 -Ile 370 ) to give rise to FXIa (2) (3) (4) (5) . The primary structures of four repeat sequences (designated A1, A2, A3, and A4 or Apple domains) present in the heavy chain region of FXI have been elucidated from the sequence of cDNA inserts coding for FXI (1) . Evidence exists for the presence of a FIX binding site on the A2 domain (6) and at the N terminus of the A3 domain (7, 8) , and a binding site for FXIIa in the A4 domain (9) . In plasma, FXI circulates in a complex with high molecular weight kininogen (HK) (10, 11) , an interaction that requires the A1 domain of FXI (12, 13) and the light chain of HK (14) . FXI can also bind to prothrombin, which can displace HK bound to FXI and which binds to a site (Ala 45 -Ser 86 ) in the A1 domain that is within the HK-binding site (15) . In the presence of HK or prothrombin, FXI can bind reversibly and specifically to high affinity sites on the surface of stimulated human platelets in the presence of zinc and calcium ions (15, 16) . More specifically, this laboratory has demonstrated that the A3 domain of FXI is essential in the binding of FXI to platelets, since a recombinant A3 (rA3) domain of FXI demonstrated specific, saturable binding and effectively competed with radiolabeled FXI in binding to the platelet surface (17) . The consequence of FXI binding to activated platelets is an acceleration of the rate of FXI activation by thrombin, FXIIa, or FXIa (15) .
Since both prothrombin (15, 18) and HK (14, 16, 19) have been shown to bind both to platelets (15, 16, 18, 19) and to FXI (14, 15) , one objective of the present study was to examine the mechanism by which HK and prothrombin promote the binding of FXI to the activated platelet, i.e. to determine whether either the FXI⅐HK complex or the FXI⅐prothrombin complex initially binds as an encounter complex to platelets via HK or prothrombin, or whether, alternatively either HK or prothrombin binds only to the FXI A1 domain resulting in exposure of the A3 domain platelet binding site. Another goal of the present study was to define the amino acids within the A3 domain of FXI that mediate its binding to platelets. The results of these studies, utilizing site-directed mutational analysis of recombinant FXI (rFXI) confirm and extend previous studies utilizing conformationally constrained synthetic peptides and the rA3 domain of FXI, which identified Arg 250 , Lys 255 , Phe 260 , and Gln 263 as important for generating the platelet-binding site (17) .
EXPERIMENTAL PROCEDURES
Materials-Human FXI and FXIa were purchased from Hematologic Technologies, Inc. (Essex Junction, VT). Restriction enzymes were obtained from New England Biolabs (Beverly, MA). DNA markers, Pfu polymerase, ligase, dNTPs, and Sephadex G-50 (fine) were purchased from Amersham Pharmacia Biotech. The human FXI cDNA was a gift from Dr. Dominic Chung (University of Washington, Seattle, WA). The region of 31 amino acids derived from HK (HK31-mer) was a gift from Dr. Werner Muller-Esterl (University of Mainz, Mainz, Germany). The Chameleon site-directed mutagenesis kit and plasmid pBluescript (SKϩ version) were purchased from Stratagene (La Jolla, CA). The 293 human fetal kidney fibroblast cell line was purchased from the American Tissue Type Collection (Manassas, VA). Bacto-tryptone, Bacto-yeast extract, Dulbecco's modified Eagle medium, and G418 were obtained from Life Technologies, Inc. Cellgro Complete serum-free medium was purchased from Mediatech (Herndon, VA). Trichloroacetic acid, ␤-mercaptoethanol, and disodium EDTA were purchased from Fisher Scientific (Springfield, NJ). Methyl silicon oil and purified by reverse-phase high performance liqud chromatography to Ͼ99% homogeneity. Normal pooled and FXI-deficient human plasmas were purchased from George King Biochemical (Overland Park, KS). All reagents and materials used for SDS-polyacrylamide gel electrophoresis were purchased from BioRad. IODOGEN vials (20 g of coating) were obtained from Pierce. Soybean trypsin inhibitor, lima bean trypsin inhibitor, aprotinin, benzamidine, HEPES, sodium m-periodate, Sepharose 2B-CL, Sephadex G25 (fine), dithiothreitol, sodium phosphate, Tris-HCl, Trizma base, cysteine, bovine serum albumin, iodoacetamide, and metabisulfite were purchased from Sigma.
Radiolabeling of Proteins-Purified proteins were radiolabeled by a minor modification of the IODOGEN method. Briefly, 2 l of 125 I-NaOH (500 -1,000 Ci/l) was added to 100 l of protein (0.1-1.0 mg/ml) and incubated in an IODOGEN vial (20-g coating) for 20 min. The reaction was stopped by adding metabisulfite (50 g/ml). Preparation of Wild Type and Mutant Human FXI-The procedures utilized to prepare wild type FXI and the FXI mutants rFXI(S248A), rFXI(T249A), rFXI(R250A), rFXI(I251A), rFXI(K252A), rFXI(K253A), rFXI(S254A), rFXI(K255A), rFXI(L257A), rFXI(F260A), rFXI(Q263A), rFXI(250 -2553 A), rFXI(249 -2513 A), rFXI(252-2543 A), rFXI (255-2573 A), and rFXI⅐PKA3 were those described by Sun et. al. (7) . Mutations were introduced into the wild type human FXI cDNA in vector pBluescript (SKϩ version) using a Chameleon site-directed mutagenesis kit, according to the manufacturer's recommendations. Proper introduction of the mutation was confirmed by conventional dideoxy chain termination DNA sequencing. cDNAs were subsequently ligated into a mammalian expression vector, pJVCMV, containing the cytomegalovirus promoter. Human fetal kidney fibroblasts (293 cells, 5 ϫ 10 7 cells) were co-transfected with 40 g of FXI cDNA/pJVCMV construct and 2 g of a plasmid RSVneo, which contains a gene conferring resistance to neomycin. Transfection was by electroporation using an Electrocell Manipulator 600 (BTX, San Diego, CA). Transfected cells were grown in Dulbecco's modified Eagle's medium with 5% fetal bovine serum for 24 h and then switched to the same medium supplemented with the neomycin analog, G418, at 500 g/ml. Medium was exchanged every 48 h. G418-resistant clones were transferred to 24-well tissue culture plates and culture supernatants were tested for protein expression by enzyme-linked immunosorbent assay, using goat anti-human FXI capture antibody and the same antibody conjugated to horseradish peroxidase for detection, as recommended by the supplier. Clones expressing the highest levels of protein were expanded to confluence in 175-cm 2 tissue culture flasks. When the cells had reached confluence, medium was replaced with 75 ml of serum-free Cellgro complete medium supplemented with 10 g/ml soybean trypsin inhibitor, 10 g/ml lima bean trypsin inhibitor, and 5 g/ml aprotinin. This mixture of protease inhibitors prevents activation or degradation of the recombinant protein in the conditioned medium. Medium was exchanged every 48 h. After collection, conditioned medium was supplemented with benzamidine to a final concentration of 5 mM and stored at Ϫ20°C pending purification.
Purification of the Recombinant Proteins-One liter of conditioned medium was passed over a 3-ml column of murine anti-human FXI monoclonal antibody, 1G5.12, linked to Affigel-10 as described previously (7). After loading, the columns were washed with 10 column volumes of 25 mM Tris-HCl, pH 7.4, 100 mM NaCl (Tris-buffered saline) supplemented with 5 mM benzamidine, followed by elution with 25 mM Tris-HCl, pH 7.4, 2 M sodium thiocyanate, 5 mM benzamidine. Proteincontaining fractions were pooled and concentrated in an Amicon concentrator, dialyzed against Tris-buffered saline, and stored at Ϫ70°C. The concentration of recombinant proteins was determined using a dye binding assay (Bio-Rad). All the recombinant proteins utilized in this study have been extensively characterized as previously reported (20) . All proteins were shown to be homogeneous and Ͼ95% pure by SDSpolyacrylamide gel electrophoresis. When zymogen proteins were converted to FXIa by incubation with FXIIa, the activated proteins cleaved the chromogenic substrate S-2366 with similar kinetic parameters compared with wild type and plasma-derived proteins (20) . All recombinant proteins had normal clotting activity (within 20% of wild type or plasma-derived FXI) when assayed in FXI-deficient plasma (20) .
Preparation of Washed Platelets-Forty-five ml of blood was collected in a 50-ml tube containing 5 ml of 2.5% trisodium citrate (w/v), 1.5% citric acid (w/v), and 2.0% dextrose (w/v). The blood was centrifuged at 800 ϫ g for 20 min. to obtain platelet-rich plasma. Platelet-rich plasma was removed to a new 50-ml tube and centrifuged again at 800 ϫ g for 5 min to remove contaminating red blood cells. This supernatant was centrifuged at 1,800 ϫ g for 15 min. The pellet was resuspended in 5 ml of HEPES-Tyrode buffer, pH 6.5, and gel-filtered on a column of Sepharose 2B equilibrated in HEPES-Tyrode buffer, pH 7.4. Platelets were counted using a particle counter from Coulter Electronics (Hialeah, FL).
Coagulation Assays-The coagulation assays were performed using the kaolin-activated partial thromboplastin time. The master reaction mixture contained 50 l of 25 mg of kaolin mixed with phospholipids (0.04% inosithin) in 5 ml of HEPES-Tyrode buffer, pH 7.4. To this mixture, 50 l of FXI-deficient plasma, 1 nM wild type FXI, or appropriate concentrations of recombinant wild type FXI or mutant rFXI-A3 proteins were added to a final volume of 200 l. This was repeated with activated platelets (10 8 /ml) substituted for phospholipids. The master mixture was incubated at 37°C for 5 min; 50 l of 50 mM CaCl 2 was then added, and the clotting time was determined.
Isolation and Purification of Prothrombin Fragment 2 (PF2) (Ser

156
to Arg
271
) from Prothrombin-Prothrombin activation material containing PF2 and depleted of thrombin by SP-Sephadex column chromatography was obtained from Enzyme Research Laboratories (South Bend, IN) and processed as follows. This preparation contained 0.4 mg/ml protein in 50 mM sodium phosphate and 1 M benzamidine, pH 6.5. To 50 ml of this material, Phe-Pro-Arg-chloromethyl ketone (Calbiochem, Indianapolis, IN) was added to a concentration of 10 M. PF2 was isolated using fast protein liquid chromatography at 23°C using a MonoQ (HR 5/5) column according to the procedure of Stevens and Nesheim (21) . Preparative isolation of the material on this column results in PF1 and PF2 in two separate pools. PF2 migrates at 14 kDa as a doublet on SDS-gel electrophoresis. From 50 ml loaded on the column, approximately 7 mg of PF2 was recovered. An identical preparation of human PF2 was obtained as a generous gift from S. Krishnaswamy (University of Pennsylvania, Philadelphia, PA) and gave identical results.
Platelet Binding Experiments-Direct binding and competition experiments were carried out as described previously (16) . For direct binding, platelets (10 8 
Binding of Factor XI and Factor XI Mutants to High Molecular Weight Kininogen on Surface Plasmon
Resonance-Binding studies were performed on a Biacore 2000 flow biosensor (Biacore, Inc., Uppsala, Sweden). High molecular weight kininogen was immobilized on a carboxymethyl dextran (CM5) flow cell surface using amine coupling chemistry. Briefly, 1.15 mg of N-hydroxysuccinimide was mixed with 7.5 mg of NЈ-(3-dimethylaminopropyl)carbodiimide hydrochloride and injected at 5 l/min, for 7 min across the flow cell surface. HK, ϳ10 g/ml in sodium acetate buffer, pH 4.5, was then injected for 1-2 min to a response level of ϳ500 response units. Any remaining derivatized carboxymethyl groups were then blocked by a 7-min injection of 1 M ethanolamine hydrochloride-NaOH. Nonspecific binding was determined by protein binding to a derivatized and blocked flow cell with an unrelated antibody bound. Serial dilutions of wild type FXI and FXI mutants in HBS, with or without 20 M zinc, 0.005% surfactant P20 (Biacore, Inc.) were injected with a 6-min association time and 5-min dissociation time. After subtraction of the nonspecific binding curves, the association and dissociation rate constants were determined using a global fit to a one to one Langmuir association model on Biaevaluation software (Biacore, Inc.). The best fit was determined by a 2 value of less than 10 or less than 5% of the equilibrium response unit value for the highest concentration. The 2 value is the square of the differences between the theoretical ideal curve and the actual curve and was calculated according to the following equation.
Where r f indicates the fitted value at a given point, r x indicates the experimental value at that point, n indicates the number of data points, and p indicates the number of fitted parameters. Statistics-Results are expressed as the mean Ϯ S.E. Statistical analysis was performed with Student's t test. p Ͻ 0.05 was considered to be statistically significant. (15) . In addition, we have determined that the interaction between prothrombin and FXI occurs through PF2 and the A1 domain of FXI (15) . Similarly, the binding of HK to the A1 domain of FXI (12) is mediated by a 31-amino acid region, 565-595, on domain 6 of HK (14) . HK, which is bound to FXI in circulation, also promotes the specific, high affinity binding of FXI to the surface of stimulated human platelets in the presence of zinc and calcium ions (16, (22) (23) (24) . FXI binding to activated platelets was demonstrated to be saturable, and nonspecific binding (measured in the presence of a 100-fold excess of unlabeled FXI) was demonstrated to be linear and to represent a small fraction (Ͻ10%) of total binding at saturation (15, 16, 25) . We, therefore, determined whether the sequences of amino acids, in both prothrombin and HK, that bind to FXI can also promote FXI binding to the activated platelet surface. Binding of various concentrations of FXI to stimulated platelets was determined in the presence of 25 M ZnCl 2 and 2 mM Furthermore, when compared with prothrombin and HK as cofactors for FXI binding to activated platelets, the HK31-mer and PF2 peptides were able to induce saturable binding in the same manner as the intact proteins (Fig. 1) . The results demonstrate that saturable binding was achieved at FXI concentrations above those present in plasma (30 nM). When saturation binding data were analyzed, the K d (ϳ10 nM) and total number of sites (1,500 -2,000 sites/platelet) were the same for the HK, HK31-mer, prothrombin, and PF2. Thus, the synthetic peptide HK31-mer or PF2 can substitute for HK or prothrombin, respectively, as a cofactor for FXI binding to platelets.
RESULTS
The Effect of HK31-mer (Ser
We also examined the binding of FXI to activated platelets in the presence or absence of ions. When HK31-mer was used as a cofactor, in the absence of zinc, the saturable binding decreased by 70%, as compared with total binding in the presence of zinc (Fig. 1) . However, when we replaced zinc with calcium, we observed suboptimal binding (Fig. 1) , suggesting that in addition to the HK31-mer, the binding of FXI to activated platelets also requires zinc ions. When PF2 was used as cofactor, the binding was specific and saturable in the presence of zinc. In the absence of zinc, specific binding was reduced by 75%. When calcium was included in the binding assay, slight enhancement of binding was observed (Fig. 1) , suggesting that the requisite ion for PF2-mediated binding of FXI is zinc and not calcium as previously reported for prothrombin (15) .
Factor XI Does Not Use High Molecular Weight Kininogen or Prothrombin as a Receptor for Binding to Activated Platelets-
The ability of cofactors to act as co-receptors for FXI binding to activated platelets was examined. The binding of 125 I-FXI (50 nM) in the presence of HK (50 nM) or in the presence of prothrombin (1 M) was titrated against an increasing concentration of HK31-mer or PF2 (Fig. 2) . It was anticipated that if HK⅐FXI or prothrombin⅐FXI complexes were binding to activated platelets via HK-or prothrombin-binding sites on platelets, then high concentrations of HK31-mer or PF2 would prevent FXI binding. The results indicated that the binding of FXI to platelets remained unchanged at high concentration of HK31-mer or PF2. Thus, these cofactors do not function as receptors for FXI on the platelet surface. This study also suggests that, even if the HK31-mer or PF2 are displacing HK or prothrombin from FXI, the platelet binding site on the A3 domain of FXI remains exposed and functional due to continued occupancy of the HK or prothrombin binding site in the FXI A1 domain by the HK31-mer or by PF2.
Binding of Factor XI to Platelets Is Mediated through the Apple 3 Domain-We have reported that a platelet-binding site exists in the A3 domain of FXI. In order to expose this site, FXI must be bound to a cofactor (HK or prothrombin) (10, 16) or alternatively, as shown in Fig. 1 , to PF2 or to the HK31-mer peptide.
Prekallikrein (PK), another blood coagulation factor with four tandem repeats that are 58% identical to FXI (17, 26), was examined to determine if it contains a platelet binding site. Our experiments demonstrated that neither PK nor a chimeric protein in which the A3 domain of FXI was replaced by that of PK (FXI⅐PKA3) binds saturably or specifically to the activated platelet surface (Fig. 3) in the presence of HK. This result demonstrates that the A3 domain of FXI mediates its binding to activated platelets. Since this FXI⅐PKA3 protein binds normally to HK (see next section, below) this result also supports the conclusion that HK does not comprise a binding site for FXI on the platelet surface.
Binding of Recombinant Factor XI and Recombinant Factor XI Mutants to High Molecular Weight Kininogen-To assure that replacement of the A3 domain of FXI with that of PK did not affect the capacity of FXI to bind to HK, binding studies were carried out using surface plasmon resonance. Additionally, either recombinant wild type FXI or FXI mutants with single alanine substitutions at selected residues within the A3 domain of FXI (S248A, R250A, K252A, K253A, K255A, L257A, F260A, and Q260A), or triple alanine mutants (249 -2513 A, 252-2543 A, and 255-2573 A), were examined for their ability to bind to HK. Each protein, at a concentration of 10 nM, was infused across a biosensor surface containing immobilized HK. The association and dissociation rate constants describing the interactions of each mutant and of wild type FXI are summarized in Table I, ϳ16.8 nM) , whereas the 252-2543 A mutant bound with a K d of 33.7 nM. These results suggest that mutation of multiple residues in this region may affect the overall conformation of FXI.
Determination of Apple 3 Domain Residues That Comprise the Platelet Binding Site in Recombinant
Factor XI-Competition binding studies were carried out with rFXI, in which specific amino acid substitutions were made (alanine multiple and single scanning), to provide clues concerning the residues that may be important for binding to platelets in the A3 domain of FXI (Fig. 4 Ϫ8 M) showed a defect in platelet binding (Table II) . Two of the multiple alanine scanning substitutions showed quantitatively similar defects, i.e. 250 -2553 A (K i ϳ9 ϫ 10 Ϫ6 M), and 249 -2513 A (K i ϳ3 ϫ 10 -6 M), whereas 252-2543 A showed no deficiency (K i ϳ1 ϫ 10 Ϫ8 M) in its ability to compete with 125 I-FXI for binding to platelets.
The Effects of Mutant Recombinant Factor XI Proteins in Coagulant Assays Containing Platelets or Phospholipids-A
previous report from our laboratory showed that the A3 domain of FXI inhibited procoagulant activity in the presence of platelets but failed to inhibit procoagulant activity in the presence of phospholipids (17) . We, therefore, carried out partial thromboplastin time coagulation assays to determine the effects of rFXI mutations on their abilities to promote surface-mediated coagulation. When phospholipids (0.04% inosithin) were used as a surface, the procoagulant activities of all mutants were normal (Table III) . However, when platelets were used as a surface (10 8 platelets/ml), the rFXI⅐PKA3 chimera had ϳ0.5% FXI activity. Additionally, the following mutants showed statistically significant (p Ͻ 0.05) defects in their FXI activity in the presence of platelets: S248A (67% FXI activity), R250A (20% FXI activity), K255A (40% FXI activity), L257A (50% FXI activity), F260A (8% FXI activity), Q263A (64% FXI activity), 250 -2553 A (5% FXI activity), 249 -2513 A (15% FXI activity), and 255-2573 A (35% FXI activity). However, the following FXI mutants were shown, statistically, to be normal in activity: 125 I-FXI (85% FXI activity), K252A (88% FXI activity), K253A (80% FXI activity), S254A (82% FXI activity), and S264A (78% FXI activity) (Table III) . Thus, the mutants shown to be normal in binding to platelets were normal in their capacity to promote platelet-mediated FXI activity, whereas the mutants shown to be abnormal in platelet binding (S248A, R250A, K255A, L257A, F260A, and Q263A) were also abnormal in plateletmediated FXI activity. Therefore, these experiments indicate that FXI interacts specifically with the platelet surface through the A3 domain and that FXI interaction with the platelet surface is an important physiological process. DISCUSSION We have previously demonstrated that both HK and prothrombin bind FXI with
respectively (15) . HK and prothrombin bind the A1 domain of FXI and can both act to promote the specific, high affinity binding of FXI to the surface of activated gel-filtered platelets (15, 16) . Additionally, it is well documented that both HK (19) and prothrombin (18) bind specifically and with high affinity to the surface of activated platelets. It has previously been un- , and Lys 255 were substituted with alanines, while residues 251 and 254 were the same as wild type FXI (E); rFXI(249 -2513 A), where all three residues were replaced with alanine (Ⅺ); rFXI(252-2543 A), where all three residues were replaced with alanine (छ); and rFXI(255-2573 A), where all three residues were replaced with alanine (‚). B, single alanine substitutions: rFXI(S248A) (ࡗ), rFXI(R250A) (OE), rFXI(K255A) (), rFXI(L257A) (ϫ), rFXI(F260A) (q), and rFXI(Q263A) (f). C, results from single alanine substitutions that do not show any effect on clear whether HK and prothrombin promote the binding of FXI to the platelet surface by acting as a receptor for binding FXI to the platelet or whether alternatively they might bind to the FXI A1 domain, possibly to induce a conformational alteration in FXI resulting in the exposure of a platelet binding site in the A3 domain. In order to determine the mechanism by which these cofactors act, we compared the saturable binding to platelets of 125 I-FXI in the presence of the known amino acid sequences of HK and prothrombin (HK31-mer and PF2) that interact with FXI and not the platelet surface (14, 15) . Our present studies support the conclusion that prothrombin and HK bind to FXI and promote exposure of the platelet binding site in the A3 domain. The evidence supporting this possibility is as follows.
1) Saturation binding data (i.e. K d and number of sites on platelets) were approximately the same when HK or HK31-mer was used as a cofactor for FXI binding to the platelets (Fig. 1A) .
2) Saturation binding data were approximately the same when prothrombin or PF2 was used as a cofactor for FXI binding to the platelets (Fig. 1B). 3) An increasing amount of cofactor (HK31-mer or PF2) did not decrease the amount of 125 I-FXI binding to the platelet surface (Fig. 2) . Thus, these cofactors are not receptors for FXI on the platelet surface.
The results of this study also confirmed our previous observation (15) that prothrombin can substitute for HK as a cofactor for the binding of FXI to activated platelets (Fig. 1) . We previously reported that FXI binding to activated platelets in the presence of the cofactor HK requires the presence of Zn 2ϩ ions, whereas when prothrombin replaced HK as the cofactor, the divalent metal ion required was Ca 2ϩ (15) . These metal ion requirements were rationalized as consistent with: 1) the presence of Zn 2ϩ binding site in HK (27) and the known Zn 2ϩ requirement for binding of HK to activated platelets (19) , and 2) the requirement for calcium binding to the ␥-carboxyglutamic acid domain of prothrombin, which is required for binding of prothrombin to activated platelets (28) . However, when the peptides, HK31-mer or PF2, were used as cofactors to promote FXI binding to activated platelets, optimal binding (K d ϳ10 nM, ϳ1,500 sites/platelet) was observed in the presence of added ZnCl 2 (25 M), whereas CaCl 2 (2 mM) was less effective (Fig. 1) . Further studies will be required to facilitate a precise understanding of the divalent metal ion requirements and mechanism, especially since both calcium ions and zinc ions are stored in platelet-dense granules and are released in soluble form (29, 30) when platelet secretion is induced by agonists such as the thrombin receptor activation peptide (SFLLRN amide), which was employed for platelet activation in the present study. It has been shown that both HK (19) , through its heavy and light chains (K d ϳ32 nM), and prothrombin (18) , through its ␥-carboxyglutamic acid domain (K d ϳ320 nM, ϳ15,000 sites/ platelet), bind to activated platelets (15) . We have previously reported that FXI binds to the surface of activated platelets (ϳ1,500 sites/platelet) with a K d ϳ5-20 nM) (15, 16, 22, 25) . We have also demonstrated that the A3 domain of FXI is directly involved in binding to platelets and can also compete with FXI for binding to the platelet surface (17) . We have previously hypothesized that a higher affinity intermediate complex is formed, whereby FXI is initially bound to the platelet through sites exposed when FXI is bound to the kringle II domain of prothrombin or HK (15) . However, the data presented in this paper suggest that intact HK or prothrombin are not required to generate this high affinity site for the platelet surface in the Our previously published work (17) used recombinant A3 domains and synthetic peptides to fine map the platelet binding site on the A3 domain. In the present study, we utilized the rFXI molecule to confirm and refine our understanding of the role of the cofactors and the platelet binding site in binding FXI to the platelet surface. Our binding competition experiments demonstrate that prekallikrein and the rFXI⅐PKA3 chimera do not bind the activated platelet surface in the presence of HK and ZnCl 2 (Fig. 3) , although they bind with normal affinity to HK (Table I) (Fig. 4 and Table II ). Our present studies indicate that the role of Phe 260 in platelet binding is uncertain since the FXI(F260A) mutant is also defective in HK binding (Table I) . Studies conducted by Tordai et. al. (31) indicated that Phe 260 is a conserved residue based on a homology search of the plasminogen/hepatocyte growth factor family. The Apple domains of prekallikrein and FXI and domains of various nematode proteins belong to the same modular superfamily referred to as the PAN module (31) . The F260A mutant was expressed at low levels in tissue culture, which also may indicate a marked conformational change in the protein. Thus, the F260A mutant might disrupt the overall conformation of FXI, prevent it from binding to HK, and prevent it from binding normally to activated platelets. In contrast, the mutations at residues Ser 248 , Arg 250 , Lys 255 , Leu 257 , and Gln 263 do not disrupt HK binding. Thus, the defect in binding characterizing these mutants is exclusively due to their ability to interact with platelet membranes. As positive controls, we used the mutants K252A and K253A, which showed normal platelet binding but abnormal heparin binding (32) ; these mutants demonstrated normal HK and platelet binding. This further solidifies our contention that FXI platelet binding is specific and is mediated by specific amino acid residues Ser 248 , Arg 250 , Lys 255 , Leu 257 , and Gln 263 . The FXI⅐PKA3 chimera had ϳ0.5% FXI coagulant activity in the presence of platelets, but 80% FXI coagulant activity in the presence of phospholipids (Table III) . Moreover, those mutant FXI proteins (S248A, R250A, K255A, F260A, Q263A) demonstrated to bind defectively to activated platelets (Table II) also had defective FXI coagulant activity in the presence of platelets but normal activity in the presence of phospholipids (Table III) . Thus, these experiments confirm the hypothesis that FXI interacts specifically, via the A3 domain, with the platelet surface. This interaction is an important process in the coagulation response.
The conclusions drawn from this study are summarized in schematic form in Fig. 5 . Two parallel mechanisms for FXI binding to the platelet surface are represented. Our data reveal that FXI does not bind the platelet surface in the absence of cofactors HK or prothrombin. The peptides of HK and prothrombin (HK31-mer and PF2) bind the A1 domain. These interactions must expose the A3 domain, allowing FXI to bind directly to the platelet surface. FXI association with the platelet surface is not mediated by its binding to either HK or prothrombin, which in turn bind directly to the platelet surface. In contrast, the interaction of FXI with either the kringle II domain of prothrombin or with HK results in the exposure of the A3 domain platelet binding site. We have confirmed this conclusion using a rFXI⅐PKA3 chimera, which did not bind the platelet surface even though it binds normally to HK or prothrombin. We have previously suggested that the binding of HK or prothrombin to the A1 domain of FXI might regulate the flux of FXI activation through the contact phase (when HK occupies this site) or through contact-independent feedback activation by thrombin (when prothrombin occupies this site). It is apparent from the present studies that these cofactors use a similar or identical mechanism to induce FXI binding to the platelet surface.
